XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Total revenue $ 114,473 $ 96,844
Biopharmaceutical and other revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 3,584 3,004
Biopharmaceutical revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 2,297 953
Contract manufacturing and testing    
Disaggregation of Revenue [Line Items]    
Total revenue $ 1,287 $ 2,051